Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-118 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive a single dose of VX-118 as a suspension in the fasted state in dosing period 1, followed by a single dose of VX-118 as tablets in the fasted state in dosing period 2, followed by a single dose of VX-118 as tablets in the fed state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods. |
| Sequence 2 | EXPERIMENTAL | Participants will receive a single dose of VX-118 as tablets in the fasted state in dosing period 1, followed by a single dose of VX-118 as tablets in the fed state in dosing period 2, followed by a single dose of VX-118 as a suspension in the fasted state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods. |
| Sequence 3 | EXPERIMENTAL | Participants will receive a single dose of VX-118 as tablets in the fed state in dosing period 1, followed by a single dose of VX-118 as a suspension in the fasted state in dosing period 2, followed by a single dose of VX-118 as tablets in the fasted state in dosing period 3. A washout period of 8 days will be maintained between the 3 dosing periods. |
| Name | Type | Description |
|---|---|---|
| VX-118 | DRUG | Tablets and Suspension for Oral Administration |
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (Kg/m\^2), both inclusive * A total body weight greater than (\>) 50 kg * Participants of non-childbearing potential Key Exclusion Criteria: * History of febrile illness or other acute illness that has not f...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
VX-118 is an investigational small molecule being developed for the treatment of cystic fibrosis. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
VX-118 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company listed on the NASDAQ under the ticker symbol VRTX.
VX-118 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 study has been completed.
VX-118 has been studied in a completed Phase 1 clinical trial with the identifier NCT06312787. The trial evaluated the relative bioavailability and food effect of a VX-118 tablet formulation in healthy volunteers.
VX-118 is a distinct investigational compound developed by Vertex Pharmaceuticals. No alternative names for VX-118 have been disclosed in public clinical trial registries.